Medpace Holdings, Inc. $MEDP Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 400.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,750 shares of the company’s stock after buying an additional 3,000 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Medpace were worth $1,801,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Allspring Global Investments Holdings LLC grew its position in Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after buying an additional 2,274 shares during the period. Cerity Partners LLC lifted its position in shares of Medpace by 41.0% during the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after acquiring an additional 23,530 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Medpace by 24,930.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after acquiring an additional 100,968 shares in the last quarter. UBS Group AG boosted its stake in shares of Medpace by 32.8% during the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock worth $184,715,000 after acquiring an additional 81,250 shares in the last quarter. Finally, Mitchell Capital Management Co. acquired a new stake in shares of Medpace in the 4th quarter worth approximately $3,383,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MEDP shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, TD Cowen increased their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Stock Up 2.5%

Shares of NASDAQ:MEDP opened at $585.49 on Thursday. The company has a market capitalization of $16.34 billion, a P/E ratio of 34.32, a P/E/G ratio of 2.55 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock’s fifty day simple moving average is $501.76 and its 200-day simple moving average is $493.30.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,087 shares of company stock valued at $16,203,054 in the last ninety days. Insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.